Analysts expect PROCEPT BioRobotics to report an earnings per share (EPS) of $-0.32. PROCEPT BioRobotics bulls will hope to ...

PROCEPT BioRobotics (NASDAQ:PRCT) reported fourth-quarter 2025 results that were marked by strong U.S. procedure growth but ...

Q4 2025 earnings call recap: revenue, procedure growth, 2026 guidance, margin drivers & risks from sales changes—read now.

Company outlines path to leadership in BPH, including near-term focus on procedure growth through patient-centric solutions and increased ...

We came across a bullish thesis on PROCEPT BioRobotics Corporation on Notes From The Beauty Contest’s Substack by ...

The Company will report financial results for the fourth quarter of 2025 after market close on Wednesday, February 25, 2026. The Company’s management will host a corresponding conference call ...

PROCEPT BioRobotics PRCT is gearing up to announce its quarterly earnings on Wednesday, 2025-08-06. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

Jefferies initiated coverage of Procept BioRobotics (PRCT) with a Hold rating and $95 price target The firm’s checks suggest the Hydros system launch could catalyze a replacement cycle among systems ...

SAN JOSE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing ...

PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics develops, manufactures and sells the ...

Detailed price information for Procept Biorobotics Corp (PRCT-Q) from The Globe and Mail including charting and trades.

Company outlines path to leadership in BPH, including near-term focus on procedure growth through patient-centric solutions and increased organizational disciplineStrong revenue outlook, procedure ...